<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03959423</url>
  </required_header>
  <id_info>
    <org_study_id>CIP321</org_study_id>
    <nct_id>NCT03959423</nct_id>
  </id_info>
  <brief_title>Safety Evaluation of the Advanced Hybrid Closed Loop (AHCL) System</brief_title>
  <official_title>Safety Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adult and Pediatric Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Diabetes</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Diabetes</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a Safety Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1
      Adult and Pediatric Subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the safety of the Advanced Hybrid Closed Loop system
      (AHCL) in type 1 diabetes adult and pediatric subjects in a home setting. The main objective
      in conducting this research is to collect data from patients who use the AHCL system at home,
      at work, at school and everywhere else.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 7, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbA1c</measure>
    <time_frame>3 months</time_frame>
    <description>The overall mean difference of the change in HbA1c from baseline to end of 3-month study period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in percentage of Euglycemia</measure>
    <time_frame>3 months</time_frame>
    <description>The overall mean change in % of time in euglycemia (70-180 mg/dL) from baseline to the end of study will be estimated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Severe Hypoglycemic Event</measure>
    <time_frame>3 months</time_frame>
    <description>Number of severe hypoglycemic events occurred during 3-month period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Diabetic Ketoacidosis (DKA) Event</measure>
    <time_frame>3 months</time_frame>
    <description>Number of Diabetic Ketoacidosis (DKA) event occurred during 3-month period</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Subjects 7-75 years of age</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who have been diagnosed with type 1 diabetes</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AHCL insulin pump system</intervention_name>
    <description>Advanced Hybrid Closed Loop insulin pump with associated CGM and blood glucose meter</description>
    <arm_group_label>Subjects 7-75 years of age</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is age 7-75 years at time of Screening

          2. Subjects 14-75 years of age: A clinical diagnosis of type 1 diabetes for 2 years or
             more as determined via medical record or source documentation by an individual
             qualified to make a medical diagnosis

          3. Subjects 7-13 years of age: A clinical diagnosis of type 1 diabetes for 1 year or more
             as determined via medical record or source documentation by an individual qualified to
             make a medical diagnosis Study-specific inclusion criteria

          4. Subject is willing to perform ≥ 4 finger stick blood glucose measurements daily

          5. Subject is willing to perform required sensor calibrations

          6. Subject is willing to wear the system continuously throughout the study

          7. Subject must have a minimum daily insulin requirement (Total Daily Dose) of greater
             than or equal to 8 units

          8. Subject has a Glycosylated hemoglobin (HbA1c) less than 10% (as processed by Central
             Lab) at time of Screening visit Note: All HbA1c blood specimens will be sent to and
             tested by a NGSP certified Central Laboratory. HbA1c testing must follow National
             Glycohemoglobin Standardization Program (NGSP) standards.

          9. Subject has TSH in the normal range OR if the TSH is out of normal reference range the
             Free T3 is below or within the lab's reference range and Free T4 is within the normal
             reference range.

         10. Pump therapy for greater than 6 months prior to screening (with or without CGM
             experience)

         11. Subject must have a companion or caregiver available at night for the duration of the
             study period who resides (or will live) in in the same building (or home). A companion
             or caregiver should also be available during exercise challenges in the same building,
             home or location (if not at home). This requirement may be verified by subject report
             at screening visit.

         12. Subject willing to upload data from the study pump, must have Internet access and a
             computer system that meets the requirements for uploading the study pump

         13. If subject has celiac disease, it has been adequately treated as determined by the
             investigator

         14. Subject is willing to take one of the following insulins and can financially support
             the use of either of the 2 insulin preparations throughout the course of the study
             (i.e. co-payments for insulin with insurance or able to pay full amount)

               -  Humalog™* (insulin lispro injection)

               -  NovoLog™* (insulin aspart)

         15. Subjects with history of cardiovascular event 1 year or more from the time of
             screening must have an EKG within 6 months prior to screening or during screening. If
             subject has an abnormal EKG, participation is allowed if there is clearance from a
             cardiologist

         16. Subjects with the 3 or more cardiovascular risk factors listed below must have an EKG
             within 6 months prior to screening or during screening. If subject has an abnormal
             EKG, participation is allowed if there is clearance from a cardiologist

             a. Cardiovascular risk factors include:

               -  Age &gt;35 years

               -  Type 1 diabetes of &gt;15 years' duration

               -  Presence of any additional risk factor for coronary artery disease

               -  Presence of microvascular disease (proliferative retinopathy or nephropathy,
                  including microalbuminuria)

               -  Presence of peripheral vascular disease

               -  Presence of autonomic neuropathy

         17. Subjects with history of cardiovascular event 1 year or more from the time of
             screening must have a stress test within 6 months prior to screening or during run in
             period. If subject fails stress test, participation is allowed if there is clearance
             from a cardiologist

        Exclusion Criteria:

          1. Subject has a history of 1 or more episodes of severe hypoglycemia, which resulted in
             any the following during the 6 months prior to Screening:

               1. Medical assistance (i.e. Paramedics, Emergency Room (ER) or Hospitalization)

               2. Coma

               3. Seizures

          2. Subject has been hospitalized or has visited the ER in the 6 months prior to Screening
             resulting in a primary diagnosis of uncontrolled diabetes

          3. Subject has had Diabetic Ketoacidosis (DKA) in the 6 months prior to Screening.

          4. Subject has Hypoglycemia Unawareness, as measured by the Gold questionnaire (Gold,
             MacLeod et al. 1994) at Screening

          5. Subject is unable to tolerate tape adhesive in the area of sensor placement

          6. Subject has any unresolved adverse skin condition in the area of sensor placement
             (e.g., psoriasis, dermatitis herpetiformis, rash, Staphylococcus infection)

          7. Women of child-bearing potential who have a positive pregnancy test at Screening or
             plan to become pregnant during the course of the study

          8. Females who are sexually active and able to conceive will be excluded if they are not
             using an effective method of contraception and do not agree to continue using an
             effective method of contraception for the duration of the study as determined by
             investigator.

          9. Subject has had any of the following cardiovascular events within 1 year of screening:
             myocardial infarction, unstable angina, coronary artery bypass surgery, coronary
             artery stenting, transient ischemic attack, cerebrovascular accident, angina,
             congestive heart failure, ventricular rhythm disturbances or thromboembolic disease

         10. Subject is being treated for hyperthyroidism at time of Screening

         11. Subject has a diagnosis of adrenal insufficiency

         12. Subject has taken any oral, injectable, or intravenous (IV) glucocorticoids within 8
             weeks from time of Screening, or plans to take any oral, injectable, or IV
             glucocorticoids during the course of the study

         13. Subject is actively participating in an investigational study (drug or device) wherein
             he/she has received treatment from an investigational study drug or investigational
             study device in the last 2 weeks

         14. Subject is currently abusing illicit drugs

         15. Subject is currently abusing marijuana

         16. Subject is currently abusing prescription drugs

         17. Subject is currently abusing alcohol

         18. Subject is using pramlintide (Symlin), DPP-4 inhibitor, liraglutide (Victoza or other
             GLP-1 agonists), metformin, canagliflozin (Invokana or other SGLT2 inhibitors) at time
             of Screening

         19. Subject has a history of visual impairment which would not allow subject to
             participate in the study and perform all study procedures safely, as determined by the
             investigator

         20. Subject has elective surgery planned that requires general anesthesia during the
             course of the study

         21. Subject has a sickle cell disease, hemoglobinopathy; or has received red blood cell
             transfusion or erythropoietin within 3 months prior to time of Screening

         22. Subject plans to receive red blood cell transfusion or erythropoietin over the course
             of study participation

         23. Subject diagnosed with current eating disorder such as anorexia or bulimia

         24. Subject has been diagnosed with chronic kidney disease that results in chronic anemia

         25. Subject has a hematocrit that is below the normal reference range of lab used.

         26. Subject is on dialysis

         27. Subject has serum creatinine of &gt;2 mg/dL.

         28. Research staff involved with the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Thomas Troub</last_name>
    <phone>818.576.3142</phone>
    <email>thomas.troub@medtronic.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Melissa Vella</last_name>
    <email>melissa.vella@medtronic.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Arkansas Diabetes and Endocrinology Center</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Scripps Whittier Diabetes Institute</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>SoCal Diabetes</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Halvorson</last_name>
      <phone>310-962-1808</phone>
      <email>halvorson@socaldiabetes.com</email>
    </contact>
    <investigator>
      <last_name>Kevin Kaiserman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Diablo Clinical Research</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Barbara Davis Center - Adults</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Barbara Davis Center - Pediatric</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Boranian</last_name>
      <phone>303-724-4608</phone>
      <email>emily.boranian@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>Robert Slover, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale Diabetes Research Program</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lori Carria</last_name>
      <phone>203-737-3595</phone>
      <email>lori.carria@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Jenn Sherr, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janet Rodriguez</last_name>
      <phone>813-974-5499</phone>
      <email>janetrodriguez@health.usf.edu</email>
    </contact>
    <investigator>
      <last_name>Dorothy Shulman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atlanta Diabetes Associates</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalie Gruber</last_name>
      <phone>404-355-4393</phone>
      <email>mailto:trials@atlantadiabetes.com</email>
    </contact>
    <investigator>
      <last_name>Bruce Bode, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southeastern Endocrine</name>
      <address>
        <city>Roswell</city>
        <state>Georgia</state>
        <zip>30076</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Diabetes Center</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joann Malone</last_name>
      <phone>208-528-9650</phone>
      <email>joann@idahomed.com</email>
    </contact>
    <investigator>
      <last_name>David Liljenquist, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>International Diabetes Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamie Hyatt</last_name>
      <phone>952-993-9668</phone>
      <email>jamie.hyatt@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Anders Carlson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AM Diabetes &amp; Endocrinology Center</name>
      <address>
        <city>Bartlett</city>
        <state>Tennessee</state>
        <zip>38133</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lesley Draffin</last_name>
      <phone>901-531-6236</phone>
      <email>ldraffin@amdiabetes.net</email>
    </contact>
    <investigator>
      <last_name>Kashif Latif, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Endocrinology</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78681</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Diabetes and Glandular Disease Clinic</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rainier Clinical Research</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital and Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sue Kearns</last_name>
      <phone>206-987-1758</phone>
      <email>ue.kearns@seattlechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Cate Pihoker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>May 20, 2019</study_first_submitted>
  <study_first_submitted_qc>May 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2019</study_first_posted>
  <last_update_submitted>March 10, 2020</last_update_submitted>
  <last_update_submitted_qc>March 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

